Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Awwwww .....

<< Previous

Bullboard Posts

Next >>

Comment by Chianchinon Mar 19, 2022 7:52am

95 Views

Post# 34527528

RE:RE:RE:Awwwww .....

I like your new alias mr. mugsy as it is appropriate though mudsh..t would have been a better one. Sick penniless dude game. For those of you that do not know on this forum Mr Mugsy previous name was Mugmod, last Year Stokhouse terminated Mugmod for having multiple aliases. So Mugmod re-appeared as Mr Mugsy with at least a DOZEN OF ALIASES. Soon Stockhouse will TERMINATE Mr. Mugsy again.

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project